- Publications -



Pictures © Vicky Bogaert

Public domain publications I have considerably contributed to:


Solassol J, Vendrell J, Märkl B, Haas C, Bellosillo B, Montagut C, Smith M, O'Sullivan B, D'Haene N, Le Mercier M, Grauslund M, Melchior LC, Burt E, Cotter F, Stieber D, Schmitt FL, Motta V, Lauricella C, Colling R, Soilleux E, Fassan M, Mescoli C, Collin C, Pagès JC and Sillekens P (2016) Multi-center evaluation of the fully automated PCR-based Idylla™ KRAS Mutation Assay for rapid KRAS mutation status determination on formalin-fixed paraffin-embedded tissue of human colorectal cancer. PLoS One 11(9): e0163444.


Melchior L, Grauslund M, Bellosillo B, Montagut C, Torres E, Moragón E, Micalessi I, Frans J, Noten V, Bourgain C, Vriesema R, van der Geize R, Cokelaere K, Vercooren N, Crul K, Rüdiger T, Buchmüller D, Reijans M and Jans C (2015) Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. Experimental and Molecular Pathology 99(3), 485-491.


Van Loock M, Van den Eynde C, Hansen J, Geluykens P, Ivens T, Sauviller S, Bunkens L, Van Acker K, Nijs E and Dams G (2013) An automated time-of-drug-addition assay to routinely determine the mode of action of HIV-1 inhibitors. Assay and Drug Development Technologies 11(8), 489-500.


Pattery T, Verlinden Y, De Wolf H, Nauwelaers D, Van Baelen K, Van Houtte M, Mc Kenna P and Villacian J (2012) Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance. Intervirology 55(2), 138-146.


Geeraert L and CAM-Cancer Consortium (2011) Ornish diet and lifestyle modification programme. Online document.

Geeraert L and CAM-Cancer Consortium (2011) Insulin potentiation therapy. Online document.

Geeraert L and CAM-Cancer Consortium (2011) Vitamin E. Online document.

Geeraert L and CAM-Cancer Consortium (2011) Intravenous high-dose vitamin C. Online document.

Coffé H and Da Roit B (2011) Party policy positions in Italy after pre-electoral coalition disintegration. Acta Politica 46, 25-42.


Coffé H, Plassa R (2010) Party policy position of DIE LINKE. A continuation of the PDS? Party Politics 16(6), 721-735.

Berke JM, Fenistein D, Pauwels F, Bobbaers R, Lenz O, Lin T-I, Krausz E and Fanning G (2010) Development of a high-content screening assay to identify compounds interfering with the formation of the hepatitis C virus replication complex. Journal of Virological Methods 165(2), 268-276.

Lenz O, Verbinnen T, Lin T-I, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC and Simmen KA (2010) In vitro resistance profile of the HCV NS3/4A protease inhibitor TMC435. Antimicrobial Agents and Chemotherapy 54(5), 1878-1887.

Coffé H and van der Lippe T (2010) Citizenship norms in Eastern Europe. Social Indicators Research 96(3), 479-496.

Reesink HW, Fanning GC, Abou Farha K, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K and Verloes R (2010) Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients. Gastroenterology 138(3), 913-921.

Cummings MD, Lindberg J, Lin T-I, de Kock H, Lenz O, Lilja E, Felländer S, Baraznenok V, Nyström S, Nilsson M, Vrang L, Edlund M, Rosenquist Å, Samuelsson B, Raboisson P and Simmen K (2010) Induced-Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target. Angewandte Chemie International Edition 49(9), 1652-1655.

Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti J-F, Bruinzeel W, Cummings MD, van Vlijmen H and Andries K (2010) Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proceedings of the National Academy of Sciences of the United States of America 107(1), 308-313.


Jochmans D, Vingerhoets J, Arnoult E, Geeraert L and Guillemont J (2009) Human Immunodefficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. In: RL LaFemina (Ed), . Antiviral research: strategies in antiviral drug discovery, pp. 33-50. ASM Press, Washington, DC.

Van Marck H, Dierynck I, Kraus G, Hallenberger S, Pattery T, Muyldermans G, Geeraert L, Borozdina L, Bonesteel R, Aston C, Shaw E, Chen Q, Martinez C, Koka V, Lee J, Chi E, de Béthune M-P and Hertogs K (2009) The impact of individual HIV-1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence. Journal of Virology 83(18), 9512-9520.

Clayton R, Ohagen A, Nicol F, Del Vecchio AM, Jonckers THM, Goethals O, Van Loock M, Michiels L, Grigsby J, Xu Z, Zhang Y, Gutshall LL, Cunningham M, Jiang H, Bola S, Sarisky RT and Hertogs K (2009) Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Research 84(2), 142-149.

Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP and Stuyver LJ (2009) Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1. Antimicrobial Agents and Chemotherapy 53(5), 2185-2188.

Lin T.-I, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, Vermeiren K, Rosenquist Å, Edlund M, Samuelsson B, Vrang L, de Kock H, Wigerinck P, Raboisson P and Simmen K (2009) In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor. Antimicrobial Agents and Chemotherapy 53(4), 1377-1385.

Nyanguile O, Devogelaere B, Vijgen L, Van den Broeck W, Pauwels F, Cummings MD, De Bondt HL, Vos AM, Berke JM, Lenz O, Vandercruyssen G, Vermeiren K, Mostmans W, Dehertogh P, Delouvroy F, Vendeville S, VanDyck K, Dockx K, Cleiren E, Raboisson P, Simmen KA and Fanning GC (2009) 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus. Journal of Virology 84(6), 2923-2934.


Geeraert L, Kraus G and Pomerantz RJ (2008) Hide-and-Seek: The Challenge of Viral Persistence in HIV-1 Infection. Annual Review of Medicine 59, 487-501.

Dams G, Van Loock M, Geeraert L, Gustin E, Bunkens L, Holemans P, Hallenberger S and Van Acker K (2008) Transferring a homogeneous flow cytometric HIV-1 entry assay to a high content platform. BIOforum Europe 6, 24.

Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G, Jochmans D, Vermeire K, Schols D, Hallenberger S and Hertogs K (2008) Resistance mutations in HIV-1 integrase selected with Elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. Journal of Virology 82(21), 10366-10374.

Gong E, Ivens T, Van den Eynde C, Hallenberger S and Hertogs K (2008) Development of antiviral assays for profiling compounds against a panel of positive-strand RNA viruses using ATP/luminescence readout. Journal of Virological Methods 151(1), 121-125.

Van Vlijmen H (2008) HIV therapie: hoe raak je een bewegend doel? Conceptuur 55, 6-7.

Jochmans D (2008) Novel HIV-1 reverse transcriptase inhibitors. Virus Research 134, 171-185.

Bonfanti J-F, Meyer C, Doublet F, Fortin J, Muller P, Queguiner L, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, van Remoortere P, Janssens F, Wigerinck P and Andries K (2008) Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). Journal of Medicinal Chemistry 51(4), 875-896.


Dams G, Van Acker K, Boutton C, Geeraert L, Meersseman G and Ohagen A (2007) Targeting the zipper of the HIV-1 spike with small molecules. SCREENING - Trends in Drug Discovery2, 30-31.

Dierynck I, De Wit M, Gustin E, Keuleers I, Vandersmissen J, Hallenberger S and Hertogs K (2007) Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. Journal of Virology 81(24), 13845-13851.

Bonfanti J-F, Doublet F, Fortin J, Lacrampe J, Guillemont J, Muller P, Queguiner L, Arnoult E, Gevers T, Janssens P, Szel H, Willebrords R, Timmerman P, Wuyts K, Janssens F, Sommen C, Wigerinck P and Andries K (2007) Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship. Journal of Medicinal Chemistry 50(19), 4572-4584.

Dams G, Van Acker K, Gustin E, Vereycken I, Bunkens L, Holemans P, Smeulders L, Clayton R, Ohagen A and Hertogs K (2007) A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion. Journal of Biomolecular Screening 12(6), 865-874.

Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D and Andries K (2007) Diarylquinolines target subunit c of mycobacterial ATP synthase. Nature Chemical Biology 3(6), 323-324.

Mordant C, Schmitt B, Pasquier E, Demestre C, Queguiner L, Masungi C, Peeters A, Smeulders L, Bettens E, Hertogs K, Heeres J, Lewi P and Guillemont J (2007) Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. European Journal of Medicinal Chemistry 42(5), 567-579.

Clayton R, Ohagen A, Goethals O, Smets A, Van Loock M, Michiels L, Kennedy-Johnston E, Cunningham M, Jiang H, Bola S, Gutshall L, Gunn G, Del Vecchio A, Sarisky R, Hallenberger S and Hertogs K (2007) Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells. Journal of Virological Methods 139(1), 17-23.


Jochmans D, Deval J, Kesteleyn B, Van Marck H, Bettens E, De Baere I, Dehertogh P, Ivens T, Van Ginderen M, Van Schoubroeck B, Ehteshami M, Wigerinck P, Götte M and Hertogs K (2006) Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action. Journal of Virology 80(24), 12283-12292.


Causeret C, Geeraert L, Van der Hoeven G, Mannaerts GP and Van Veldhoven PP (2000) Further characterization of rat dihydroceramide desaturase: tissue distribution, subcellular localization, and substrate specificity. Lipids 35(10), 1117-1125.


Geeraert L, Mannaerts GP and van Veldhoven PP (1997) Conversion of dihydroceramide into ceramide: involvement of a desaturase. Biochemical Journal 327(Pt 1), 125-132.

Go back up